Modality
mRNA
MOA
EGFRi
Target
PD-L1
Pathway
Cell Cycle
Hemophilia ALGS
Development Pipeline
Preclinical
Apr 2019
→ Sep 2027
PreclinicalCurrent
NCT08713344
2,207 pts·Hemophilia A
2019-04→2027-09·Not yet recruiting
2,207 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-021.4y awayInterim· Hemophilia A
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Not yet…
Catalysts
Interim
2027-09-02 · 1.4y away
Hemophilia A
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08713344 | Preclinical | Hemophilia A | Not yet recr... | 2207 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 |